โ
๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ
โข Adj. EPS: $1.42 (Est. $1.41) โ
โข Revenue: $13.01B (Est. $12.99B) ๐ฐ, +14.5% YoY.
โข GAAP EPS: $0.53.
โข Comparable Sales Growth: +7.0% YoY.
โข Nutrition Revenue: $2.26B, +5.1% YoY.
โข Diagnostics Revenue: $3.31B, +46.7% YoY.
โข Established Pharmaceuticals Revenue: $1.61B, +6.8% YoY.
โข Medical Devices Revenue: $5.83B, +6.9% YoY.
โ
๐ฏ ๐๐ฎ๐ข๐๐๐ง๐๐
โข FY2026 Adj. EPS: $5.50โ$5.55, midpoint $5.525 (Est. $5.52) ๐ฐ, range tightened, midpoint reaffirmed.
โข Q4 2026 Adj. EPS: $1.62โ$1.67, midpoint $1.645 (Est. $1.64) ๐ฐ
โข FY2026 Comparable Sales Growth: ~6.0%.
โ
๐ ๐๐๐ฒ ๐๐๐ค๐๐๐ฐ๐๐ฒ๐ฌ
โข Q3 Adj. EPS beat consensus by ~0.7%, while revenue was broadly in line with expectations.
โข Comparable sales grew 7% YoY across all four segments, led by Established Pharmaceuticals (+8.4%) and Medical Devices (+7.8%).
โข Diagnostics reported revenue surged 46.7%, reflecting the Exact Sciences acquisition, while comparable growth was 6.4%.
โข Cancer Diagnostics comparable revenue grew 13.8%, supported by Cologuard and precision oncology.
โข Medical Devices growth was led by Electrophysiology (+15.5% comparable) and Rhythm Management (+10%), while Diabetes Care grew 6.7%.
โข Abbott reaffirmed its FY2026 Adj. EPS midpoint at ~$5.53, broadly matching consensus.
โข Key product developments included FDA approvals for Libre Duo and TactiFlex Duo, alongside the launch of the SimpleScreen CRC blood-based cancer screening test.
โ
๐ฌ ๐๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ ๐๐จ๐ฆ๐ฆ๐๐ง๐ญ๐๐ซ๐ฒ
โAbbott delivered strong third-quarter results, reflecting balanced growth across our portfolio.โ